Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria
about
Safety of besifloxacin ophthalmic suspension 0.6% in cataract and LASIK surgery patientsSafety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patientsThe safety of besifloxacin ophthalmic suspension 0.6 % used three times daily for 7 days in the treatment of bacterial conjunctivitisBesifloxacin: Efficacy and Safety in Treatment and Prevention of Ocular Bacterial InfectionsIntegrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes.Antibacterial efficacy of prophylactic besifloxacin 0.6% and moxifloxacin 0.5% in patients undergoing cataract surgery.Safety of besifloxacin ophthalmic suspension 0.6% as a prophylactic antibiotic following routine cataract surgery: results of a prospective, parallel-group, investigator-masked study.Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infectionsContribution of the R8 substituent to the in vitro antibacterial potency of besifloxacin and comparator ophthalmic fluoroquinolones.Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis.Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates.Besifloxacin ophthalmic suspension, 0.6%: a novel topical fluoroquinolone for bacterial conjunctivitis.Besifloxacin ophthalmic suspension: emerging evidence of its therapeutic value in bacterial conjunctivitis.Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile.In vitro activity of bioactive extracts from rare actinomycetes against multi-drug resistant Streptococcus pneumoniae.Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis.Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae.Biosynthesis of the antibiotic nonribosomal peptide penicillin in baker's yeastRecombinant Endolysins as Potential Therapeutics against Antibiotic-Resistant Staphylococcus aureus: Current Status of Research and Novel Delivery Strategies.Identification of potential antimicrobials against Salmonella typhimurium and Listeria monocytogenes using Quantitative Structure-Activity Relation modeling.Simple Isocratic HPLC Method for Determination of Enantiomeric Impurity in Besifloxacin Hydrochloride.Rhodium-catalyzed enantioselective hydrogenation of α-amino acrylonitriles: an efficient approach to synthesizing chiral α-amino nitriles.Preparation and evaluation of novel chitosan: gelrite ocular system containing besifloxacin for topical treatment of bacterial conjunctivitis: scintigraphy, ocular irritation and retention assessment.Microbiological etiology and susceptibility of bacterial conjunctivitis isolates from clinical trials with ophthalmic, twice-daily besifloxacin.
P2860
Q24562648-530C2C4C-043B-4220-9B12-42E5D0973A48Q24631003-DBEC6078-5F84-4167-8AA7-7DAFC077AFD9Q24631812-7BB0C54D-EDB8-426A-A937-B0518DB98937Q26752242-F43C2C24-68C1-4A75-A205-9BCC3052CF9EQ35410079-113242B9-3754-42D5-AEF9-4DD96D189048Q35617621-B8B3C79F-8913-43A9-964F-39B82FE555A4Q36026870-651B73F0-9D53-4C95-84C3-21FF3818B658Q36451350-EB4C0EEB-61F3-4216-B0C6-5F3382A0E715Q36825816-B8DE91D1-985B-438C-B465-FA5A9D90A543Q37594797-F55E5B6E-30E7-499C-85CF-9931FF0961F2Q37653431-38C15F71-88B8-4E4C-A903-97C8808FB48DQ38021408-1990EAA1-28D2-4911-B991-A1FF840AF73EQ38122147-53172AA5-9522-4C26-BE80-0AD6AF9A407CQ38779535-BCBCE708-4C0A-45B5-95C4-58F7F69D3304Q39526130-53DE4517-2B2D-45DD-9018-A836BC53DBA7Q40273599-3F1DC3CA-FF1D-45C1-8A98-2A293019BAD4Q40953254-83712473-5455-40B9-B934-38DEF1C55A13Q42191279-7964D16F-3567-4957-A29B-1F01561E2FE2Q46251747-41EF989B-78C6-4E25-B424-E2F2F4829643Q47134841-D57CB16D-D933-430E-BEFB-389AB4FD6EC8Q48093311-50BD37A7-88F2-4C16-AE22-BEABF0403D32Q48368248-9A6CDF01-B4C9-486A-96E8-48E15289FD22Q50529018-BB71FA4D-3A82-4486-A480-DED212FAF4D6Q50941259-E2C8CAEF-09FB-48BD-90AC-C7FC25B594E0
P2860
Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Besifloxacin, a novel fluoroqu ...... aerobic and anaerobic bacteria
@ast
Besifloxacin, a novel fluoroqu ...... aerobic and anaerobic bacteria
@en
Besifloxacin, a novel fluoroqu ...... aerobic and anaerobic bacteria
@nl
type
label
Besifloxacin, a novel fluoroqu ...... aerobic and anaerobic bacteria
@ast
Besifloxacin, a novel fluoroqu ...... aerobic and anaerobic bacteria
@en
Besifloxacin, a novel fluoroqu ...... aerobic and anaerobic bacteria
@nl
prefLabel
Besifloxacin, a novel fluoroqu ...... aerobic and anaerobic bacteria
@ast
Besifloxacin, a novel fluoroqu ...... aerobic and anaerobic bacteria
@en
Besifloxacin, a novel fluoroqu ...... aerobic and anaerobic bacteria
@nl
P2093
P2860
P356
P1476
Besifloxacin, a novel fluoroqu ...... aerobic and anaerobic bacteria
@en
P2093
Chris M Pillar
Gary E Zurenko
Jacqueline C Lee
Lynne S Brunner
Timothy W Morris
Wolfgang Haas
P2860
P304
P356
10.1128/AAC.00418-09
P407
P577
2009-06-08T00:00:00Z